文献速递脑血管病

女性在卒中临床试验中的代表性:281项试验超50万参与者的综述

Representation of Women in Stroke Clinical Trials: A Review of 281 Trials Involving More Than 500,000 Participants.
PubMed 文献 · Neurology · 2021-10-13

该综述分析1990至2020年间281项卒中随机对照试验共588,887名参与者,女性占37.4%。以参与-患病比(PPR)衡量,女性整体代表性低于其人群患病比例(平均PPR 0.84,95%CI 0.81-0.87),且1990至2020年间无显著改善(趋势P=0.201)。

要点

  • 卒中试验中女性参与者比例低于其人群患病比例,平均PPR为0.84。
  • 脑出血试验、平均年龄<70岁试验、非急性干预和康复试验中性别差异更大。
  • 1990至2020年间女性代表性不足的情况无显著变化。

核心结论

  • 女性在卒中试验中的代表性相对于人群疾病负担显著不足。
  • 需要明确指南和有效实施策略以改善女性纳入。

研究设计与样本

  • 从ClinicalTrials.gov识别1990至2020年间发表的、参与者≥100人的随机对照试验。
  • 共纳入281项卒中试验,总计588,887名参与者。

主要发现

  • 女性占全部参与者的37.4%。
  • 整体平均PPR为0.84(95%CI 0.81-0.87),女性代表性低于其人群患病比例。
  • 脑出血试验PPR为0.73(95%CI 0.71-0.74),平均年龄<70岁试验PPR为0.81(95%CI 0.78-0.84)。
  • 非急性干预试验PPR为0.80(95%CI 0.76-0.84),康复试验PPR为0.77(95%CI 0.71-0.83)。
  • 1990至2020年间上述差异无显著变化(趋势P=0.201)。

临床怎么用

  • 解读卒中干预证据时需注意女性代表性不足可能影响结果外推。
  • 设计卒中试验时应关注女性纳入比例,尤其是脑出血、非急性干预和康复领域。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Women have been underrepresented in cardiovascular disease clinical trials but there is less certainty over the level of disparity specifically in stroke. We examined the participation of women in trials according to stroke prevalence in the population. METHODS: Published randomized controlled trials with ≥100 participants enrolled between 1990 and 2020 were identified from ClinicalTrials.gov. To quantify sex disparities in enrollment, we calculated the participation to prevalence ratio (PPR), defined as the percentage of women participating in a trial vs the prevalence of women in the disease population. RESULTS: There were 281 stroke trials eligible for analyses with a total of 588,887 participants, of whom 37.4% were women. Overall, women were represented at a lower proportion relative to their prevalence in the underlying population (mean PPR 0.84; 95% confidence interval [CI] 0.81-0.87). The greatest differences were observed in trials of intracerebral hemorrhage (PPR 0.73; 95% CI 0.71-0.74), trials with a mean age of participants <70 years (PPR 0.81; 95% CI 0.78-0.84), nonacute interventions (PPR 0.80; 95% CI 0.76-0.84), and rehabilitation trials (PPR 0.77; 95% CI 0.71-0.83). These findings did not significantly change over the period from 1990 to 2020 (p for trend = 0.201). DISCUSSION: Women are disproportionately underrepresented in stroke trials relative to the burden of disease in the population. Clear guidance and effective implementation strategies are required to improve the inclusion of women and thus broader knowledge of the impact of interventions in clinical trials.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Carcel C, Harris K, Peters SAE, et al. Representation of Women in Stroke Clinical Trials: A Review of 281 Trials Involving More Than 500,000 Participants. Neurology. 2021. PMID: 34645708. doi:10.1212/WNL.0000000000012767

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。